Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dickensian winter disappears

OXFORD - London biotech stocks, like their U.S. counterparts, have seen massive price increases since mid-October, with BioCentury's London Index rising 132 percent over the period. Various fund managers see little evidence that biotech enthusiasm will slow down any time soon.

As in the U.S., internal and

Read the full 464 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers